I-Delcath Systems, I-HEPZATO KIT

I-Melphalan igunyazwe yi-FDA njengokwelashwa okuqondiswe esibindini kwe-uveal melanoma

Nov 2023: Ukuphathwa Kwezokudla Nezidakamizwa kugunyaze i-HEPZATO KIT (melphalan for Injection/Hepatic Delivery System, Delcath Systems, Inc.) njengokwelashwa okuqondiswe esibindini ezigulini ezikhulile ezinemelanoma ye-uveal ezine-h..

China, Izivivinyo zemitholampilo, i-hepatocellular carcinoma, I-JW Therapeutics, Shanghai

I-JW Therapeutics Imemezela Ukuqaliswa Kwezifundo Zomtholampilo ze-JWATM214 Ezigulini ezine-Advanced Hepatocellular Carcinoma

I-SHANGHAI, ECHINA, Februwari 28, 2023 - I-JW Therapeutics (HKEX: 2126), inkampani ezimele nentsha ye-biotechnology egxile ekuthuthukiseni, ekukhiqizeni nasekuthengiseni imikhiqizo ye-cell immunotherapy, imemezele init.

i-durvalumab, i-hepatocellular carcinoma, tremelimumab

I-Tremelimumab ivunywe yi-FDA ihlanganiswe ne-durvalumab ye-hepatocellular carcinoma engatholakali.

November 2022: The Food and Drug Administration approved tremelimumab (Imjudo, AstraZeneca Pharmaceuticals) in combination with durvalumab for adult patients with unresectable hepatocellular carcinoma (uHCC). Efficacy was evaluat..

I-Atezolizumab, Bevacizumab, nivolumab, I-Regorafenib, I-Stivarga, I-Tecentriq

Izidakamizwa ezigunyazwe ukwelapha umdlavuza wesibindi

Dec 2021: Izidakamizwa ezilandelayo zivunyelwe kusukela manje ukuze zelashwe umdlavuza wesibindi:. Sicela uhlole imininingwane yokunquma ngaphambi kokuthatha umuthi. I-Atezolizumab Avastin (Bevacizumab) i-Bevacizumab Cabometyx (Cabozantinib-SM..

Ukufakelwa kwesibindi, Ukufakelwa kwesibindi e-Apollo Chennai

Ukuhlinzwa komdlavuza wesibindi nokufakelwa kabusha nguDkt.Selvakumar

July 14, 2021: Check out interview of Dr. Selvakumar Naganathan - Clinical Lead - Liver transplantation and HPB surgery, Apollo Hospitals, Chennai. Check out the video and also excerpts of the interview. https://www.youtube.com..

I-Atezolizumab, Bevacizumab, Izidakamizwa zakamuva

I-Atezolizumab kanye neBevacizumab yokwelashwa komdlavuza wesibindi

NgoJulayi 13 ka-2021: Kutholakala umuthi omusha wabantu abanohlobo lomdlavuza wesibindi obizwa nge-hepatocellular carcinoma obonakala ungcono kunokwelashwa okujwayelekile (HCC). Ukuphathwa Kwezokudla Nezidakamizwa (i-FDA) kuvunyelwe i-atezoliz ..

I-CABOMETYX, I-Cabozantinib, Exelixis, FDA, HCC, i-hepatocellular carcinoma, Sorafenib, USFDA

ICabozantinib ivunyiwe yi-FDA nge-hepatocellular carcinoma

  On January 14, 2019, cabozantinib (CABOMETYX, Exelixis, Inc.) was approved by the Food and Drug Administration for patients with hepatocellular carcinoma (HCC) who have previously been treated with sorafenib. The appr..

Ukwelashwa komdlavuza wesibindi ngo-2023

Umthwalo womdlavuza wesibindi Umdlavuza wesibindi uyisimila esiyingozi esivamile esithatha ngaphezu kwesigamu somdlavuza wesibindi womhlaba wonke. Ukuqala kwe-hepatocellular carcinoma (HCC) kufihliwe, futhi izimpawu zakuqala azibonakali. Abantu abaningi ..

I-immunotherapy yakamuva ekwelashweni komdlavuza wesibindi

Liver cancer Liver cancer is currently the fifth most common cause of cancer-related death in the world. The current first-line systemic treatment drug is mainly sorafenib, but usually only prolongs the overall survival of 3 mont..

I-NK Cell immunotherapy ezimeni zomdlavuza wesibindi ezithuthukile

Cases of NK cell immunotherapy for advanced liver cancer 92-year-old advanced cancer patient has complete remission Seven years ago, Ms. M, who was in her 80s, was diagnosed with hepatocellular carcinoma (caused by cancer in the p..